| Literature DB >> 33363216 |
Shriya Khurana1, Christina Chemmachel1, Ramesh Saxena1.
Abstract
Most episodes of peritoneal dialysis (PD)-associated peritonitis are caused by skin-dwelling gram-positive bacteria and gram-negative bacteria colonizing gut and urinary tract. Occasionally, however, uncommon bacteria can cause peritonitis in PD patients. We describe a case of Ewingella americana peritonitis, the first such case reported from the United States. A 68-year-old woman with end-stage kidney disease due to hypertension was initiated on PD 2 years prior to the present event. She presented with abdominal pain associated with nausea and vomiting. She was afebrile and hemodynamically stable. Abdomen was diffusely tender with guarding and rebound. No obvious root cause was apparent. Initial PD fluid white count was 502/mm3 with 87% neutrophils. Gram stain was negative. Culture grew gram-negative rods, which were later identified as Ewingella americana, resistant to ampicillin and cefazolin but sensitive to gentamicin, ceftazidime, and cefepime. After empiric intraperitoneal vancomycin and gentamicin, she was continued on intraperitoneal gentamicin for a total period of 21 days. She responded to the treatment rapidly with complete recovery. PD fluid on day four showed 40 nucleated cells with 12% neutrophils. Patient remained on PD without consequences. Ewingella americana is a gram-negative facultative anaerobic bacillus that can survive in water, including domestic water. Inadequate hand hygiene is a potential root cause of infection. Although rare, Ewingella peritonitis can be observed in PD patients and is treatable. Clinicians should be aware of Ewingella as a potential cause of PD peritonitis.Entities:
Keywords: Ewingella americana; Peritoneal dialysis; Peritonitis
Year: 2020 PMID: 33363216 PMCID: PMC7747055 DOI: 10.1159/000510147
Source DB: PubMed Journal: Case Rep Nephrol Dial
Peritoneal fluid analysis
| Peritoneal fluid | Day 1 | Day 2 | Day 4 |
|---|---|---|---|
| Color | Straw | Yellow | Yellow |
| Turbidity | Hazy | Hazy | Clear |
| RBC count (/mm3) | 20 | 70 | 0 |
| WBC count (/mm3) | 502 | 6,000 | 40 |
| Lymphocyte, % | 1 | 1 | 14 |
| Neutrophil, % | 87 | 89 | 12 |
| Monocyte, % | 10 | 10 | 69 |
Case reports of Ewingella americana peritonitis in PD patients reported worldwide
| Case 1 [ | Case 2 [ | Case 3 [present study] | |
|---|---|---|---|
| Age, years | 70 | 76 | 68 |
| Gender | Female | Female | Female |
| Ethnicity | Greek | Chinese | African American |
| Cause of ESKD | Polycystic kidney disease | Not specified | Hypertension |
| PD schedule | Continuous ambulatory peritoneal dialysis | Continuous ambulatory peritoneal dialysis | Continuous cycler-assisted peritoneal dialysis |
| Previous peritonitis episodes | Unknown | Unknown | |
| Duration of PD (prior to | 5 years | 10 months | 2 years |
| Root cause | Not identified | Unknown | Likely break in sterile technique |
| Presenting symptoms | Diffuse abdominal pain, | Generalized abdominal pain, decreased appetite, left chest pain and pressure − worse at night | Diffuse abdominal pain, nausea, vomiting |
| Signs on physical exam | Abdominal tenderness, positive rebound | Abdominal tenderness, positive rebound | Abdominal tenderness, guarding +, rebound + |
| Dialysate | Turbid, 400 WBCs/mm3 with neutrophil predominance | Turbid, 400 WBCs/mm3 with neutrophil predominance | Hazy, initial 502, later 6,000 WBCs/mm3 with neutrophil predominance |
| Empiric antibiotic used | Intravenous vancomycin and amikacin | Intravenous vancomycin | IP vancomycin and gentamicin |
| Antibiotic susceptibility | Ampicillin, amoxicillin - clavulanate, ceftazidime, ceftriaxone, cefotaxime, cefepime, ofoxacin, gentamicin, carbenicillin, amikacin | Tobramycin, ceftazidime, cefepime, aztreonam, imipenem, amikacin, gentamicin, ciprofloxacin, piperacillin, levofloxacin | Ampicillin-sulbactam, piperacillin-tazobactam, ceftriaxone, ceftazidime, cefepime, gentamicin, levofloxacin, imipenem, trimethoprim-sulphamethoxazole |
| Antibiotic resistance | Cephalothin, penicillin G, vancomycin | Ampicillin, ampicillin-sulbactam, cefazolin, cefotetan, ertapenem, trimethoprim-sulfamethoxazole, nitrofurantoin | Ampicillin, cefazolin, cefuroxime |
| Management | Vancomycin discontinued, continued on amikacin | Vancomycin switched to amikacin | Vancomycin discontinued, gentamicin continued |
| Duration of antibiotic treatment | Amikacin administered until complete recovery | Amikacin administered until complete patient recovery | Gentamicin given for a total period of 3 weeks |
| Outcome | Complete recovery | Complete recovery | Complete recovery, patient continued on PD without complications |
ESKD, end-stage kidney disease; PD, peritoneal dialysis; IP, intraperitoneal.